Tearsheet

NovoCure (NVCR)

Market Price (9/18/2025): $12.7 | Market Cap: $1.4 Bil
Sector: Health Care | Industry: Life Sciences Tools & Services

NovoCure (NVCR)

Market Price (9/18/2025): $12.7
Market Cap: $1.4 Bil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15%	Weak multi-year price returns 2Y Excs Rtn is -84%, 3Y Excs Rtn is -146%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -173 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -27%
1	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -41%		Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -7.1%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -13%
2			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -17%

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15%
1	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -41%
2	Weak multi-year price returns 2Y Excs Rtn is -84%, 3Y Excs Rtn is -146%
3	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -173 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -27%
4	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -7.1%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -13%
5	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -17%

Market Valuation

	9/18/25	2024	2023	2022	2021
Share Price CYE	$12.70	$29.80	$14.93	$73.35	$75.08
Market Cap CYE ($ Bil)	1.4	3.2	1.6	7.7	7.8
Total Debt ($ Bil)	0.7	0.7	0.6	0.6	0.6
Total Cash ($ Bil)	0.9	1.0	0.9	1.0	0.9
Enterprise Value ($ Bil)	1.2	3.9	2.2	8.3	8.4
Valuation Ratios
P/S TTM	2.2	5.3	3.1	14.3	14.5
P/EBIT TTM	-11.5	-26.6	-8.4	-97.8	-159.7
P/E TTM	-8.3	-19.1	-7.7	-83.0	-133.1
Sector Ratios
P/S TTM (Sector)	3.8	3.6	4.1	4.5	7.3
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4	-1.3	-2.9
P/E TTM (Sector)	-1.8	-1.5	-1.5	-1.3	-2.9

	9/18/25	2024	2023
Share Price CYE	$12.70	$29.80	$14.93
Market Cap CYE ($ Bil)	1.4	3.2	1.6
Total Debt ($ Bil)	0.7	0.7	0.6
Total Cash ($ Bil)	0.9	1.0	0.9
Enterprise Value ($ Bil)	1.2	3.9	2.2
Valuation Ratios
P/S TTM	2.2	5.3	3.1
P/EBIT TTM	-11.5	-26.6	-8.4
P/E TTM	-8.3	-19.1	-7.7
Sector Ratios
P/S TTM (Sector)	3.8	3.6	4.1
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4
P/E TTM (Sector)	-1.8	-1.5	-1.5

Stock Price
Market Cap

Stock Price Chart

Return (1Y):

Market Cap Chart

Business Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. Show more

Price Returns Compared

Expand for Detailed View

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
NVCR Return	105%	-57%	-2%	-80%	100%	-57%	-86%
Peers Return	29%	50%	-12%	4%	-13%	-5%	46%
S&P 500 Return	16%	27%	-19%	24%	23%	12%	104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: LEGN, TMO, DHR, A, IQV. See NVCR Returns vs. Peers.
[3] 2025 data is for the year up to 9/17/2025 (YTD)

Better Bets than NovoCure (NVCR)

	NVCR	Better Performance than NVCR
Metric	Value	Industry (Life Sciences Tools & Services)
Rev Chg LTM	14.6%	NTRA (44.4%), GH (28.2%), IRTC (22.4%), WGS (48.7%), ATEC (26.3%)
Rev Chg 3Y Avg	5.3%	NTRA (39.7%), MEDP (20.4%), EXAS (14.9%), GH (25.6%), IRTC (22.1%)
Op Mgn LTM	-27.4%	TMO (18.2%), DHR (18.4%), A (21.3%), IQV (14.4%), MTD (28.4%)
CFO/Rev LTM	-7.1%	TMO (17.5%), DHR (25.7%), A (22.0%), IQV (16.7%), MTD (24.6%)
FCF/Rev LTM	-12.8%	TMO (14.3%), DHR (20.2%), A (16.0%), IQV (12.8%), MTD (21.9%)
Total Yield	-12.1%	TMO (3.7%), DHR (2.5%), A (4.2%), IQV (3.9%), MTD (3.1%)

	NVCR	Better Performance than NVCR
Metric	Value	Sector (Health Care)
Rev Chg LTM	14.6%	LLY (36.8%), ISRG (20.8%), BSX (21.4%), MCK (20.3%), CI (24.6%)
Rev Chg 3Y Avg	5.3%	LLY (23.4%), UNH (11.3%), ISRG (15.4%), AMGN (10.0%), BSX (14.6%)
Op Mgn LTM	-27.4%	LLY (43.0%), JNJ (24.5%), ABBV (23.5%), UNH (7.3%), ABT (17.4%)
CFO/Rev LTM	-7.1%	LLY (20.5%), JNJ (25.4%), ABBV (33.1%), UNH (6.8%), ABT (21.0%)
FCF/Rev LTM	-12.8%	LLY (-0.1%), JNJ (18.1%), ABBV (31.3%), UNH (6.0%), ABT (15.7%)
Total Yield	-12.1%	LLY (2.8%), JNJ (8.1%), ABBV (3.9%), UNH (9.4%), ABT (7.7%)

	NVCR	Better Performance than NVCR
Metric	Value	All Other Sectors
Rev Chg LTM	14.6%	NVDA (71.6%), MSFT (14.9%), META (19.4%), AVGO (28.0%), NFLX (14.8%)
Rev Chg 3Y Avg	5.3%	NVDA (92.0%), MSFT (12.5%), GOOGL (10.2%), AMZN (11.3%), META (13.0%)
Op Mgn LTM	-27.4%	NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM	-7.1%	NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM	-12.8%	NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), AMZN (2.0%)
Total Yield	-12.1%	NVDA (2.1%), MSFT (3.3%), AAPL (3.2%), GOOGL (4.1%), AMZN (2.9%)

Latest Trefis Analyses

	Title	Topic	Date
0	DASHBOARDS
1	Day 5 of Loss Streak for NovoCure Stock with -34% Return (vs. -63% YTD) [7/30/2025]	Notification
2	NVCR Dip Buy Analysis
3	NovoCure (NVCR) Stock: 38% of days in last 3 months had 1% or greater fluctuation
4	NovoCure (NVCR) Operating Cash Flow Comparison	Financials
5	NovoCure (NVCR) Net Income Comparison	Financials
6	NovoCure (NVCR) Operating Income Comparison	Financials
7	NovoCure (NVCR) Revenue Comparison	Financials
8	NovoCure vs. S&P500 Correlation	Correlation
9	NovoCure Price Volatility	Volatility
10	NovoCure Total Shareholder Return (TSR): 99.6% in 2024 and -26.5% 3-yr compounded annual returns (below peer average)
11	ARTICLES
12	NVCR Stock Down -34% after 5-Day Loss Streak		July 31st, 2025
13	Stocks Trading At 52-Week Low		July 29th, 2025
14	Market Movers \| Winners: BE, WST, ICLR \| Losers: CYH, NVCR, IRDM		July 25th, 2025
15	Will Novocure Stock Rebound After A Large 22% Fall In A Month?		November 24th, 2021
16	What’s Next For Novocure Stock?		April 14th, 2021

	Title
0	DASHBOARDS
1	NVCR Stock Down -34% after 5-Day Loss Streak
2	Stocks Trading At 52-Week Low
3	Market Movers \| Winners: BE, WST, ICLR \| Losers: CYH, NVCR, IRDM
4	Will Novocure Stock Rebound After A Large 22% Fall In A Month?
5	What’s Next For Novocure Stock?
6	ARTICLES
7	Day 5 of Loss Streak for NovoCure Stock with -34% Return (vs. -63% YTD) [7/30/2025]
8	NVCR Dip Buy Analysis
9	NovoCure (NVCR) Stock: 38% of days in last 3 months had 1% or greater fluctuation
10	NovoCure (NVCR) Operating Cash Flow Comparison
11	NovoCure (NVCR) Net Income Comparison
12	NovoCure (NVCR) Operating Income Comparison
13	NovoCure (NVCR) Revenue Comparison
14	NovoCure vs. S&P500 Correlation
15	NovoCure Price Volatility
16	NovoCure Total Shareholder Return (TSR): 99.6% in 2024 and -26.5% 3-yr compounded annual returns (below peer average)

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	ECDA	ECD Automotive Design	3937.1%	307.9%
2	ATHA	Athira Pharma	890.3%	544.3%
3	SPRC	SciSparc	142.9%	1141.7%
4	ATCH	AtlasClear	87.4%	-83.1%
5	GV	Visionary	68.2%	14.8%
6	APLM	Apollomics	51.3%	89.1%
7	SQFT	Presidio Property Trust	46.3%	11.0%
8	CDT	CDT Equity	40.1%	-99.1%
9	EDUC	Educational Development	31.8%	9.1%
10	ILLR	Triller	29.8%	-37.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	CURX	Curanex Pharmaceuticals	-83.5%	148.4%
2	CODX	Co-Diagnostics	-34.7%	-44.4%
3	BOXL	Boxlight	-34.5%	-13.5%
4	OPI	Office Properties Income Trust	-31.8%	-40.9%
5	BIAF	bioAffinity Technologies	-30.0%	-79.9%
6	ENVB	Enveric Biosciences	-29.3%	-88.0%
7	KAVL	Kaival Brands Innovations	-27.3%	-46.7%
8	AEI	Alset	-25.5%	211.8%
9	INBS	Intelligent Bio Solutions	-25.0%	0.7%
10	LVRO	Lavoro	-23.0%	-67.2%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	ECDA	ECD Automotive Design	3347.2%	307.9%
2	BDSX	Biodesix	1090.6%	-79.7%
3	CLSD	Clearside Biomedical	987.7%	-74.7%
4	ATHA	Athira Pharma	892.1%	544.3%
5	SDOT	Sadot	690.6%	-79.9%
6	ATCH	AtlasClear	684.9%	-83.1%
7	HSDT	Helius Medical Technologies	232.1%	-95.5%
8	CHEK	Check-Cap	222.2%	134.4%
9	APLM	Apollomics	197.8%	89.1%
10	SPRC	SciSparc	147.0%	1141.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	CURX	Curanex Pharmaceuticals	-80.5%	148.4%
2	ATYR	aTyr Pharma	-80.4%	-71.7%
3	NAKA	Kindly MD	-70.2%
4	BNGO	Bionano Genomics	-64.0%	-89.8%
5	XAGE	Longevity Health	-57.6%	-86.1%
6	FAAS	DigiAsia	-55.4%	-88.0%
7	ASST	Strive	-54.5%	650.3%
8	VCIG	VCI Global	-51.0%	-98.9%
9	REX	REX American Resources	-50.7%	44.3%
10	RBNE	Robin Energy	-42.6%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PMI	Picard Medical	11931.7%	11931.7%
2	GIBO	GIBO	10714.0%
3	LNZA	LanzaTech Global	8455.2%	-86.3%
4	GTI	Graphjet Technology	3998.4%	-93.1%
5	GWAV	Greenwave Technology Solutions	3582.8%	-91.4%
6	QMMM	QMMM	3409.6%	8153.1%
7	ECDA	ECD Automotive Design	2715.2%	307.9%
8	OESX	Orion Energy Systems	1373.7%	14.2%
9	OP	OceanPal	1266.5%	-95.6%
10	BCTX	BriaCell Therapeutics	1032.4%	-89.8%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	CJET	Chijet Motor	-94.5%	-96.0%
2	STFS	Star Fashion Culture	-92.3%	-97.9%
3	ELPW	Elong Power	-91.1%	-76.9%
4	NXTT	Next Technology	-90.1%	-95.4%
5	EPIX	ESSA Pharma	-89.4%	-8.9%
6	NAKA	Kindly MD	-88.1%
7	BINI	Bollinger Innovations	-87.6%	-100.0%
8	JEM	707 Cayman	-87.4%	-98.2%
9	YAAS	Youxin Technology	-83.3%	-98.4%
10	NEON	Neonode	-82.5%	-51.0%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	ECDA	ECD Automotive Design	3937.1%	307.9%
2	ATHA	Athira Pharma	890.3%	544.3%
3	SPRC	SciSparc	142.9%	1141.7%
4	ATCH	AtlasClear	87.4%	-83.1%
5	GV	Visionary	68.2%	14.8%
6	APLM	Apollomics	51.3%	89.1%
7	SQFT	Presidio Property Trust	46.3%	11.0%
8	CDT	CDT Equity	40.1%	-99.1%
9	EDUC	Educational Development	31.8%	9.1%
10	ILLR	Triller	29.8%	-37.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	CURX	Curanex Pharmaceuticals	-83.5%	148.4%
2	CODX	Co-Diagnostics	-34.7%	-44.4%
3	BOXL	Boxlight	-34.5%	-13.5%
4	OPI	Office Properties Income Trust	-31.8%	-40.9%
5	BIAF	bioAffinity Technologies	-30.0%	-79.9%
6	ENVB	Enveric Biosciences	-29.3%	-88.0%
7	KAVL	Kaival Brands Innovations	-27.3%	-46.7%
8	AEI	Alset	-25.5%	211.8%
9	INBS	Intelligent Bio Solutions	-25.0%	0.7%
10	LVRO	Lavoro	-23.0%	-67.2%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	ECDA	ECD Automotive Design	3347.2%	307.9%
2	BDSX	Biodesix	1090.6%	-79.7%
3	CLSD	Clearside Biomedical	987.7%	-74.7%
4	ATHA	Athira Pharma	892.1%	544.3%
5	SDOT	Sadot	690.6%	-79.9%
6	ATCH	AtlasClear	684.9%	-83.1%
7	HSDT	Helius Medical Technologies	232.1%	-95.5%
8	CHEK	Check-Cap	222.2%	134.4%
9	APLM	Apollomics	197.8%	89.1%
10	SPRC	SciSparc	147.0%	1141.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	CURX	Curanex Pharmaceuticals	-80.5%	148.4%
2	ATYR	aTyr Pharma	-80.4%	-71.7%
3	NAKA	Kindly MD	-70.2%
4	BNGO	Bionano Genomics	-64.0%	-89.8%
5	XAGE	Longevity Health	-57.6%	-86.1%
6	FAAS	DigiAsia	-55.4%	-88.0%
7	ASST	Strive	-54.5%	650.3%
8	VCIG	VCI Global	-51.0%	-98.9%
9	REX	REX American Resources	-50.7%	44.3%
10	RBNE	Robin Energy	-42.6%

Peer Comparisons for NovoCure

Financials

	NVCR	LEGN	TMO	DHR	A	IQV	Median
Name	NovoCure	Legend B.	Thermo F.	Danaher	Agilent .	IQVIA
Mkt Price	12.69	-	472.64	192.94	126.72	186.69	186.69
Mkt Cap	1.4	-	178.7	138.2	36.0	32.1	36.0
Rev LTM	630	-	43,211	24,013	6,788	15,700	15,700
Op Inc LTM	-173	-	7,860	4,417	1,444	2,263	2,263
FCF LTM	-80	-	6,170	4,862	1,088	2,010	2,010
FCF 3Y Avg	-77	-	6,662	5,733	1,308	1,806	1,806
CFO LTM	-45	-	7,578	6,169	1,495	2,617	2,617
CFO 3Y Avg	-44	-	8,206	7,013	1,662	2,433	2,433

Growth & Margins

	NVCR	LEGN	TMO	DHR	A	IQV	Median
Name	NovoCure	Legend B.	Thermo F.	Danaher	Agilent .	IQVIA
Rev Chg LTM	14.6%	-	2.0%	1.9%	4.5%	3.6%	3.6%
Rev Chg 3Y Avg	5.3%	-	0.3%	-2.6%	0.8%	3.6%	0.8%
Rev Chg Q	5.6%	-	3.0%	3.4%	10.1%	5.3%	5.3%
QoQ Delta Rev Chg LTM	1.4%	-	0.7%	0.8%	2.4%	1.3%	1.3%
Op Mgn LTM	-27.4%	-	18.2%	18.4%	21.3%	14.4%	18.2%
Op Mgn 3Y Avg	-32.9%	-	17.4%	21.6%	21.5%	13.7%	17.4%
QoQ Delta Op Mgn LTM	-0.6%	-	-0.1%	-1.9%	-0.1%	-0.3%	-0.3%
CFO/Rev LTM	-7.1%	-	17.5%	25.7%	22.0%	16.7%	17.5%
CFO/Rev 3Y Avg	-7.8%	-	19.1%	29.9%	24.6%	16.0%	19.1%
FCF/Rev LTM	-12.8%	-	14.3%	20.2%	16.0%	12.8%	14.3%
FCF/Rev 3Y Avg	-13.6%	-	15.5%	24.4%	19.4%	11.9%	15.5%

Valuation

	NVCR	LEGN	TMO	DHR	A	IQV	Median
Name	NovoCure	Legend B.	Thermo F.	Danaher	Agilent .	IQVIA
Mkt Cap	1.4	-	178.7	138.2	36.0	32.1	36.0
P/S	2.2	-	4.1	5.8	5.3	2.0	4.1
P/EBIT	-11.5	-	21.3	31.7	23.8	14.4	21.3
P/E	-8.3	-	27.1	40.5	29.5	25.9	27.1
P/CFO	-31.7	-	23.6	22.4	24.1	12.3	22.4
Total Yield	-12.1%	-	3.7%	2.5%	4.2%	3.9%	3.7%
Dividend Yield	0.0%	-	0.0%	0.0%	0.8%	0.0%	0.0%
FCF Yield 3Y Avg	-3.6%	-	3.6%	3.4%	3.7%	5.3%	3.6%
D/E	0.5	-	0.2	0.1	0.1	0.5	0.2
Net D/E	-0.1	-	0.2	0.1	0.1	0.4	0.1

Returns

	NVCR	LEGN	TMO	DHR	A	IQV	Median
Name	NovoCure	Legend B.	Thermo F.	Danaher	Agilent .	IQVIA
1M Rtn	5.0%	-	-3.0%	-7.7%	7.3%	-3.0%	-3.0%
3M Rtn	-24.5%	-	20.5%	-0.6%	9.9%	20.7%	9.9%
6M Rtn	-34.3%	-	-8.7%	-8.0%	4.1%	-0.1%	-8.0%
12M Rtn	-29.6%	-	-22.3%	-28.8%	-7.7%	-22.2%	-22.3%
3Y Rtn	-85.4%	-	-11.9%	-20.5%	-0.3%	-8.9%	-11.9%
1M Excs Rtn	2.6%	-	-5.3%	-10.0%	4.9%	-5.4%	-5.3%
3M Excs Rtn	-37.5%	-	10.9%	-11.6%	-0.9%	10.8%	-0.9%
6M Excs Rtn	-52.0%	-	-26.7%	-26.6%	-14.2%	-18.5%	-26.6%
12M Excs Rtn	-49.0%	-	-39.7%	-46.6%	-24.3%	-39.1%	-39.7%
3Y Excs Rtn	-146.4%	-	-78.2%	-85.5%	-68.0%	-78.2%	-78.2%

Comparison Analyses

	Title
0	Novocure Limited vs. BeiGene: With Return Forecast Of 84%, Novocure Limited Is A Better Bet
1	Novocure Limited vs. Zillow: With Return Forecast Of 93%, Novocure Limited Is A Better Bet
2	Novocure Limited vs. Hubbell: With Return Forecast Of 93%, Novocure Limited Is A Better Bet
3	Novocure Limited vs. American Airlines: With Return Forecast Of 93%, Novocure Limited Is A Better Bet
4	Novocure Limited vs. AGCO: With Return Forecast Of 66%, Novocure Limited Is A Better Bet
5	Novocure Limited vs. Teva Pharmaceutical Industries: With Return Forecast Of 66%, Novocure Limited Is A Better Bet
6	Novocure Limited vs. A.O. Smith: With Return Forecast Of 66%, Novocure Limited Is A Better Bet
7	Novocure Limited vs. Lamb Weston: With Return Forecast Of 112%, Novocure Limited Is A Better Bet
8	Novocure Limited vs. Allegion: With Return Forecast Of 112%, Novocure Limited Is A Better Bet
9	Novocure Limited vs. Royal Gold: With Return Forecast Of 112%, Novocure Limited Is A Better Bet

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	6/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	7/24/2025	2/27/2025	2/22/2024	2/23/2023	2/24/2022	2/25/2021	2/27/2020
Key Financials
Total Revenue	630	605	509	538	535	494	351
EBITDA	-111	-110	-177	-68	-38	45	14
Operating Income	-173	-170	-233	-90	-44	30	-1
Net Income	-171	-169	-207	-93	-58	20	-7
EPS	-1.56	-1.56	-1.95	-0.88	-0.56	0.20	-0.07
Growth Rates
Total Revenue Growth	14.6%	18.8%	-5.3%	0.5%	8.2%	40.7%	41.6%
EBITDA Growth	14.4%	38.2%	-161.4%	-76.9%	-185.6%	231.9%	165.4%
Operating Income Growth	6.6%	26.8%	-160.1%	-101.9%	-245.8%	3426.1%	97.3%
Net Income Growth	-1.3%	18.6%	-123.7%	-58.6%	-394.6%	374.0%	88.6%
Margins
EBITDA Margin	-17.6%	-18.1%	-34.8%	-12.6%	-7.2%	9.1%	3.8%
Operating Income Margin	-27.4%	-28.2%	-45.7%	-16.6%	-8.3%	6.1%	-0.3%
Net Income Margin	-27.1%	-27.9%	-40.6%	-17.2%	-10.9%	4.0%	-2.1%
Cash & Debt
Total Cash	912	960	911	969	938	843	326
Total Debt	700	683	605	584	575	444	164
Net Debt / (Cash)	-211	-277	-306	-385	-362	-398	-163
Cash Flows
Net Cash from Operations	-45	-26	-73	31	83	99	27
Free Cash from Operations	-80	-69	-100	9	59	84	16
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	7/24/2025	4/24/2025	2/27/2025	10/30/2024	7/25/2024	5/2/2024	2/22/2024	10/26/2023	7/27/2023	5/4/2023	2/23/2023	10/27/2022
Key Financials Quarterly
Total Revenue	159	155	161	155	150	139	134	127	126	122	128	131
Ebitda	-36	-35	-11	-30	-31	-39	-5	-55	-60	-58	-29	-22
Operating Income	-40	-38	-63	-32	-34	-42	-52	-58	-63	-60	-43	-25
Net Income	-40	-34	-66	-31	-33	-39	-47	-49	-57	-53	-37	-27
EPS	-0.36	-0.31	-0.61	-0.28	-0.31	-0.36	-0.45	-0.46	-0.54	-0.50	-0.36	-0.25
Key Financials TTM
Total Revenue TTM	630	622	605	578	550	526	509	504	508	522	538	543
Ebitda TTM	-111	-105	-110	-104	-129	-159	-177	-202	-169	-127	-68	-64
Operating Income TTM	-173	-167	-170	-159	-185	-214	-233	-224	-190	-149	-90	-70
Net Income TTM	-171	-164	-169	-150	-169	-193	-207	-197	-174	-141	-93	-82
Growth Rates Quarterly
Total Revenue Growth	5.6%	11.9%	20.5%	21.8%	19.3%	13.4%	4.2%	-2.8%	-10.5%	-11.2%	-3.6%	-2.0%
EBITDA Growth	-17.4%	10.8%	-131.6%	46.5%	48.7%	32.7%	84.5%	-152.6%	-224.5%	-3288.9%	-16.9%	-277.3%
Operating Income Growth	-17.7%	8.8%	-22.4%	44.9%	46.4%	31.1%	-20.3%	-136.7%	-196.6%	-7375.1%	-83.7%	-187.8%
Net Income Growth	-20.3%	11.5%	-40.0%	38.2%	41.9%	27.0%	-26.2%	-86.2%	-139.2%	-1041.8%	-41.0%	-102.5%
Margins Quarterly
EBITDA Margin	-22.7%	-22.3%	-6.5%	-19.1%	-20.4%	-27.9%	-3.4%	-43.5%	-47.6%	-47.1%	-22.8%	-16.8%
Operating Income Margin	-24.9%	-24.4%	-39.3%	-20.7%	-22.3%	-30.0%	-38.7%	-45.7%	-49.7%	-49.3%	-33.5%	-18.8%
Net Income Margin	-25.3%	-22.1%	-40.9%	-19.7%	-22.2%	-28.0%	-35.2%	-38.9%	-45.6%	-43.4%	-29.0%	-20.3%
Cash & Debt
Total Cash	912	929	960	960	951	870	911	921	941	958	969	970
Total Debt	700	697	683	676	675	595	605	590	587	586	584	580
Net Debt / (Cash)	-211	-232	-277	-284	-276	-275	-306	-331	-353	-372	-385	-391
Cash Flows Quarterly
FCF from Operations	-16	-36	-3	10	-2	-32	-15	-19	-23	-17	-4	22
Cash Flows TTM
FCF from Operations TTM	-45	-30	-26	-37	-67	-88	-73	-62	-21	18	31	49
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-11.6%	-11.5%	-20.5%	-11.0%	-11.7%	-15.0%	-19.9%	-23.3%	-26.3%	-27.0%	-20.6%	-12.4%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-12.6%	-12.7%	-13.8%	-13.6%	-16.2%	-19.3%	-22.3%	-22.4%	-20.0%	-16.7%	-10.7%	-8.8%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Tumor Treating Fields (TTFields) Segment	509	538	535	494	351
Total	509	538	535	494	351

Price Behavior

Behavior Stats
Betas Matrix

Price Behavior

Market Price	$12.69
Market Cap ($ Bil)	1.4
First Trading Date	10/02/2015
Distance from 52W High	-62.0%
	50 Days	200 Days
DMA Price	$13.02	$19.30
DMA Trend	down	down
Distance from DMA	-2.5%	-34.2%
	3M	1YR
Volatility	65.8%	79.4%
Downside Capture	241.56	175.49
Upside Capture	-39.99	111.44
Correlation (SPY)	24.5%	30.3%

NVCR Betas & Captures as of 8/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	1.89	1.96	2.17	1.10	1.31	1.20
Up Beta	2.49	5.75	4.63	1.42	1.17	1.22
Down Beta	1.77	1.22	1.28	0.68	1.19	1.07
Up Capture	196%	-158%	-34%	44%	118%	47%
Bmk +ve Days	10	22	35	71	142	415
Stock +ve Days	12	19	27	57	116	349
Down Capture	138%	242%	320%	130%	137%	107%
Bmk -ve Days	11	19	27	54	106	334
Stock -ve Days	9	21	33	65	128	395

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date	8292025
Short Interest: Shares Quantity	5,965,015
Short Interest: % Change Since 8152025	8.2%
Average Daily Volume	1,220,993
Days-to-Cover Short Interest	4.89
Basic Shares Quantity	111,572,191
Short % of Basic Shares	5.3%

Returns Analyses

	Title
0	NovoCure Stock Return Comparison
1	[10/5/2021] Novocure Limited (NVCR) Stock Price Forecast: AI Forecasts NVCR Stock Price To Be Around $115 In A Month (Up 4.2%)
2	NovoCure Total Shareholder Return (TSR): -2.3% in 2022 and -4.5% 3-yr returns (above peer average)

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
7/24/2025	-24.0%	-33.6%	-27.9%
4/24/2025	4.4%	2.1%	1.9%
1/13/2025	-0.3%	-4.7%	-22.7%
10/30/2024	0.6%	-1.6%	16.6%
7/25/2024	-0.7%	21.2%	-9.6%
5/2/2024	11.4%	25.8%	72.8%
1/8/2024	11.6%	0.6%	11.7%
10/26/2023	-7.5%	-7.0%	-11.4%
...
SUMMARY STATS
# Positive	9	11	13
# Negative	14	12	10
Median Positive	4.4%	6.6%	11.7%
Median Negative	-6.3%	-5.8%	-13.8%
Max Positive	12.0%	25.8%	72.8%
Max Negative	-24.0%	-33.6%	-27.9%

	Forward Returns
7/24/2025	-24.0%	-33.6%	-27.9%
4/24/2025	4.4%	2.1%	1.9%
1/13/2025	-0.3%	-4.7%	-22.7%
10/30/2024	0.6%	-1.6%	16.6%
7/25/2024	-0.7%	21.2%	-9.6%
5/2/2024	11.4%	25.8%	72.8%
1/8/2024	11.6%	0.6%	11.7%
10/26/2023	-7.5%	-7.0%	-11.4%
7/27/2023	-15.9%	-25.4%	-25.6%
5/4/2023	1.2%	8.4%	20.6%
1/9/2023	-16.3%	-13.8%	-15.2%
10/27/2022	0.2%	5.4%	10.8%
7/28/2022	-5.0%	-1.7%	15.1%
4/28/2022	0.3%	6.6%	4.2%
1/10/2022	-0.9%	4.3%	13.7%
10/28/2021	-8.2%	-0.4%	-12.4%
7/29/2021	-9.9%	-15.8%	-26.8%
4/29/2021	-0.1%	-1.8%	-2.0%
1/11/2021	-0.2%	-1.7%	9.8%
10/29/2020	6.8%	5.7%	9.9%
7/30/2020	12.0%	14.7%	19.9%
4/30/2020	-10.5%	-11.9%	-8.3%
1/13/2020	-3.7%	9.8%	7.5%
SUMMARY STATS
# Positive	9	11	13
# Negative	14	12	10
Median Positive	4.4%	6.6%	11.7%
Median Negative	-6.3%	-5.8%	-13.8%
Max Positive	12.0%	25.8%	72.8%
Max Negative	-24.0%	-33.6%	-27.9%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
6302025	7242025	10-Q 6/30/2025
3312025	4242025	10-Q 3/31/2025
12312024	2272025	10-K 12/31/2024
9302024	10302024	10-Q 9/30/2024
6302024	7252024	10-Q 6/30/2024
3312024	5022024	10-Q 3/31/2024
12312023	2222024	10-K 12/31/2023
9302023	10262023	10-Q 9/30/2023
6302023	7272023	10-Q 6/30/2023
3312023	5042023	10-Q 3/31/2023
12312022	2232023	10-K 12/31/2022
9302022	10272022	10-Q 9/30/2022
6302022	7282022	10-Q 6/30/2022
3312022	4282022	10-Q 3/31/2022
12312021	2242022	10-K 12/31/2021
9302021	10282021	10-Q 9/30/2021

Insider Activity

Expand for More

	Owner	Title	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	Brackmann Christoph	Chief Financial Officer	7302025	Buy	11.63	10,000	116,300	1,525,274	Form
1	Stafford Kristin		6042025	Sell	17.28	999	17,259	52,762	Form
2	LEUNG GABRIEL		6042025	Sell	17.31	999	17,297	1,406,448	Form
3	Madden Martin J.		6042025	Sell	17.19	999	17,176	321,058	Form
4	Scannell Timothy J		6042025	Sell	17.32	999	17,299	104,211	Form

Collapse to Preview

	Owner	Title	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	Brackmann Christoph	Chief Financial Officer	7302025	Buy	11.63	10,000	116,300	1,525,274	Form
1	Stafford Kristin		6042025	Sell	17.28	999	17,259	52,762	Form
2	LEUNG GABRIEL		6042025	Sell	17.31	999	17,297	1,406,448	Form
3	Madden Martin J.		6042025	Sell	17.19	999	17,176	321,058	Form
4	Scannell Timothy J		6042025	Sell	17.32	999	17,299	104,211	Form
5	HILLEMAN JERYL L		6042025	Sell	17.26	999	17,247	96,522	Form
6	Ocean Allyson J		6042025	Sell	17.29	999	17,269	52,792	Form
7	VERNON W ANTHONY		6042025	Sell	17.35	999	17,329	2,912,269	Form
8	Hung David		6042025	Sell	17.30	999	17,280	210,934	Form
9	Leonard Frank X	EVP, Pres., Novocure Oncology	6042025	Sell	17.22	21,717	373,958	3,046,681	Form
10	Paravasthu Mukund	Chief Operating Officer	5052025	Sell	17.91	592	10,604	1,496,697	Form
11	Weinberg Uri	Chief Innovation Officer	3042025	Sell	18.92	268	5,071	3,145,600	Form
12	Leonard Frank X	EVP, Pres., Novocure Oncology	3042025	Sell	18.54	2,527	46,841	2,663,166	Form
13	Cordova Ashley	Chief Executive Officer	3042025	Sell	18.54	2,053	38,055	3,781,498	Form
14	Paravasthu Mukund	Chief Operating Officer	3042025	Sell	18.54	250	4,634	540,759	Form
15	Weinberg Uri	Chief Innovation Officer	3032025	Sell	18.78	4,326	81,254	3,133,368	Form
16	Leupin Nicolas	Chief Medical Officer	3032025	Sell	19.92	830	16,535	1,001,952	Form
17	Puri Michal Nath	Chief Human Resources Officer	3032025	Sell	19.92	1,162	23,149	2,170,112	Form
18	Leonard Frank X	EVP, Pres., Novocure Oncology	3032025	Sell	19.92	10,277	204,737	3,007,390	Form
19	Cordova Ashley	Chief Executive Officer	3032025	Sell	19.92	9,345	186,170	4,187,723	Form
20	Paravasthu Mukund	Chief Operating Officer	3032025	Sell	19.92	1,379	27,472	598,812	Form
21	Paravasthu Mukund	Chief Operating Officer	1152025	Sell	26.81	2,160	57,906	842,776	Form
22	Paravasthu Mukund	Chief Operating Officer	11062024	Sell	16.69	44	734	57,716	Form
23	Puri Michal Nath	Chief Human Resources Officer	11042024	Sell	15.79	810	12,792	1,738,611	Form
24	Leonard Frank X	EVP, Pres., Novocure Oncology	11042024	Sell	15.94	598	9,531	2,569,731	Form
25	Paravasthu Mukund	Chief Operating Officer	11042024	Sell	15.88	160	2,540	55,619	Form

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

NovoCure (NVCR)

Market Price (9/18/2025): $12.7 | Market Cap: $1.4 BilSector: Health Care | Industry: Life Sciences Tools & Services

NovoCure (NVCR)

Market Price (9/18/2025): $12.7Market Cap: $1.4 BilSector: Health CareIndustry: Life Sciences Tools & Services

Investment Highlights

Market Valuation

Stock Price Chart

Market Cap Chart

Business Description

Price Returns Compared

Interactive Breakdown

Better Bets than NovoCure (NVCR)

Latest Trefis Analyses

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for NovoCure

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (9/18/2025): $12.7 | Market Cap: $1.4 Bil
Sector: Health Care | Industry: Life Sciences Tools & Services

Market Price (9/18/2025): $12.7
Market Cap: $1.4 Bil
Sector: Health Care
Industry: Life Sciences Tools & Services